Neurogene Q1 net loss widens on higher R&D costs

Neurogene

12/05/2026 21:13

Overview

U.S. gene therapy developer's Q1 net loss widened due to higher R&D expenses

Company has dosed ~90% of participants in Embolden trial for Rett syndrome

Cash position expected to fund operations through Q1 2028

Result Drivers

R&D SPENDING - Co said higher Q1 R&D expenses were mainly due to increased Rett syndrome clinical trial costs, manufacturing and controls expenses, and more R&D staff

G&A EXPENSES OFFSET - Higher corporate and pre-commercial costs, along with increased employee-related expenses and professional fees, were offset by a decrease in non-cash stock-based compensation

Company press release: ID:nBw7T5kB9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$30.93 mln
Q1 Operating Expenses
$33.35 mln
Q1 Operating Income
-$33.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Neurogene Inc is $69.00, about 123.4% above its May 11 closing price of $30.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)